06/28/22 6:10 AMNasdaq : ROIV, ROIVW earningsRoivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business UpdatePotential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity launched for plaque psoriasis in 25 years; product and samples are now available across the US, a robust patient support program is in placeRHEA-AIneutral
06/28/22 6:00 AMNasdaq : ROIV, ROIVW Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and LupusBrepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful results Priovant is developing brepocitinib in severe autoimmune diseasesRHEA-AIneutral
06/15/22 4:30 PMNasdaq : ROIV, ROIVW conferencesearningsRoivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, todayRHEA-AIneutral
05/24/22 6:00 AMNasdaq : ROIV, ROIVW fda approvalFDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years- EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and secondary endpoints and demonstrated highly statistically significant improvement versus vehicle in Physician Global Assessment (PGA) score with 36% of patients versus 6% in vehicle in PSOARING 1 and 40% ofRHEA-AIpositive
05/19/22 4:30 PMNasdaq : ROIV, ROIVW conferencesRoivant to Present at Upcoming Investor ConferencesRoivant Sciences (Nasdaq: ROIV) will participate in four upcoming healthcare investor conferences: UBS Global Healthcare Conference in New York City on Monday, May 23 at 9:15 a.m. EDT. CEO Matt Gline willRHEA-AIneutral
05/16/22 7:00 AMNasdaq : ROIV, ROIVW Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT)Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announcedRHEA-AIneutral
05/02/22 7:00 AMNasdaq : ROIV, ROIVW managementRoivant Appoints Chief Development Officer and Announces Multiple Collaborations in Targeted Protein DegradationDr. Srini Ramanathan has over 20 years of experience in drug development and joins Roivant from Horizon Therapeutics where he built scientific R&D capabilities and teams to advance the company’s preclinical and clinical portfolio In addition to internal pipeline programs, Roivant companiesRHEA-AIpositive
03/25/22 8:01 AMNasdaq : ROIV, ROIVW clinical trialDermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual MeetingTapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with no associated tachyphylaxis Tapinarof was well-tolerated in sensitive skin and intertriginous areas with majority of patients experiencing no irritation forRHEA-AIneutral
03/11/22 4:45 PMNasdaq : ROIV, ROIVW conferencesRoivant to Present at Targeted Protein Degradation ConferenceRoivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at Guggenheim’s Targeted Protein Degradation Day on Wednesday, March 16, 2022 at 1:15 p.m. ET. A live webcast will beRHEA-AIneutral
02/28/22 6:01 AMNasdaq : ROIV, ROIVW Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against ModernaGenevant Sciences, a leading nucleic acid delivery company, and Arbutus Biopharma Corporation (Nasdaq: ABUS) today filed a lawsuit in the U.S. DistrictRHEA-AInegative
